Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.

Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG.

Vaccine. 2013 Dec 2;31(49):5848-55. doi: 10.1016/j.vaccine.2013.09.069. Epub 2013 Oct 10.

PMID:
24120675
[PubMed - indexed for MEDLINE]
2.

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A.

Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20.

PMID:
21690242
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG.

Clin Vaccine Immunol. 2012 Oct;19(10):1633-40. Epub 2012 Aug 15.

PMID:
22896687
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Kastenmüller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, Pokalwar S, Singh S, Dutta S, Ockenhouse CF, Zavala F, Seder RA.

Infect Immun. 2013 Mar;81(3):789-800. doi: 10.1128/IAI.01108-12. Epub 2012 Dec 28.

PMID:
23275094
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity.

Fung HW, Mikasa TJ, Vergara J, Sivananthan SJ, Guderian JA, Duthie MS, Vedvick TS, Fox CB.

J Nanobiotechnology. 2013 Dec 21;11:43. doi: 10.1186/1477-3155-11-43.

PMID:
24359024
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN.

J Control Release. 2013 Nov 28;172(1):190-200. doi: 10.1016/j.jconrel.2013.07.030. Epub 2013 Aug 9.

PMID:
23933525
[PubMed - indexed for MEDLINE]
7.

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Brando C, Ware LA, Freyberger H, Kathcart A, Barbosa A, Cayphas S, Demoitie MA, Mettens P, Heppner DG, Lanar DE.

Infect Immun. 2007 Feb;75(2):838-45. Epub 2006 Nov 13.

PMID:
17101665
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Optimized subunit vaccine protects against experimental leishmaniasis.

Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler RN, Vedvick TS, Reed SG.

Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.

PMID:
19786136
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.

PMID:
22425788
[PubMed - indexed for MEDLINE]
10.

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.

Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M.

Vaccine. 2011 Apr 12;29(17):3284-92. doi: 10.1016/j.vaccine.2011.02.022. Epub 2011 Feb 22.

PMID:
21349366
[PubMed - indexed for MEDLINE]
11.

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.

PMID:
19679214
[PubMed - indexed for MEDLINE]
12.

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.

Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, Jin H, Woo J.

PLoS One. 2012;7(12):e51618. doi: 10.1371/journal.pone.0051618. Epub 2012 Dec 28.

PMID:
23284726
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Jones GJ, Steinbach S, Clifford D, Baldwin SL, Ireton GC, Coler RN, Reed SG, Vordermeier HM.

Vaccine. 2013 Oct 25;31(45):5250-5. doi: 10.1016/j.vaccine.2013.08.051. Epub 2013 Sep 5.

PMID:
24012566
[PubMed - indexed for MEDLINE]
15.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
[PubMed - indexed for MEDLINE]
16.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

PMID:
20826614
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL.

Infect Immun. 2004 Feb;72(2):949-57.

PMID:
14742540
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

PMID:
21098232
[PubMed - indexed for MEDLINE]
Free Article
19.

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, Brane L, Ruane D, Teixeira A, Bozzacco L, Steinman RM, Longhi MP.

Eur J Immunol. 2012 Jan;42(1):101-9. doi: 10.1002/eji.201141855. Epub 2011 Dec 12.

PMID:
22002164
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.

Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.

Malar J. 2011 Dec 13;10:359. doi: 10.1186/1475-2875-10-359.

PMID:
22166048
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk